IN-DATE
R501-20: LivaNova Cardioplegia Cannula, Antegrade Aortic-Root, 2.0mm x 140mm
Sign in to add this product to your favorites!
| Price: | $49.00 per box of 10 |
|---|---|
| Quantity: | |
| In Stock: | 2 box of 10 |
| Status: | expired |
| Express: | Need it tomorrow? Order in next 12 hours 35 minutes and choose overnight shipping at checkout. |
Additional Details
LivaNova Cardioplegia Cannula
Antegrade Aortic-Root
The Aortic root cannulae are intended to cannulate the aortic root for cardioplegic solution delivery into the coronary arteries, and for venting of the heart during cardiopulmonary bypass surgery for periods up to six hours. The Aortic root cannulae with pressure line are intended to cannulate the aortic root for cardioplegic solution delivery into the coronary arteries, and for venting of the heart during cardiopulmonary bypass surgery for periods up to six hours. The pressure line allows pressure measurements in the aortic root.
AccessGUDID Info
- FDA Product Code: DWF
- FDA Product Code Name: CATHETER, CANNULA AND TUBING, VASCULAR, CARDIOPULMONARY BYPASS
- GMDN Term Code: 47799
- GMDN Term Name: Cardioplegia cannula
- GMDN Term Description: A sterile, single lumen, tubular device designed to deliver cardioplegic solution to the aortic root to stop the beating of the heart and maintain it dormant; it may also be used to vent the aorta and the left heart during a cardiopulmonary bypass procedure. It is typically made of plastic [e.g., polypropylene, polyvinyl chloride (PVC)] with a soft insertion tip and a suture flange for its anchoring; it may have one or more tubes (a second for aspiration, if needed), and typically Luer connector(s) for connection to the infusion syringe and aspiration line(s). It may include a manual tubing clamp and insertion is typically achieved with a removable stylet. This is a single-use device.
Manufacturer
LivaNova PLC is a global leader in medical technology, specializing in innovative solutions for cardiac surgery, neuromodulation, and cardiopulmonary support. Headquartered in London, England, and with operations worldwide, LivaNova combines decades of expertise with cutting-edge research to develop life-changing devices and therapies. Its diverse portfolio includes advanced systems for heart-lung machines, implantable neuromodulation devices for epilepsy and depression, and solutions for managing heart valve and coronary conditions. Renowned for its commitment to improving patient outcomes and enhancing quality of life, LivaNova collaborates closely with healthcare professionals to drive innovation and deliver exceptional care in the treatment of complex conditions.
